vs

Side-by-side financial comparison of Porch Group, Inc. (PRCH) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $121.1M, roughly 1.3× Porch Group, Inc.). Porch Group, Inc. runs the higher net margin — -3.9% vs -5.5%, a 1.6% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 100.0%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 26.4%).

Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

PRCH vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$121.1M
PRCH
Growing faster (revenue YoY)
TARS
TARS
+28.4% gap
TARS
128.4%
100.0%
PRCH
Higher net margin
PRCH
PRCH
1.6% more per $
PRCH
-3.9%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
26.4%
PRCH

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PRCH
PRCH
TARS
TARS
Revenue
$121.1M
$151.7M
Net Profit
$-4.7M
$-8.4M
Gross Margin
52.7%
Operating Margin
34.7%
-5.3%
Net Margin
-3.9%
-5.5%
Revenue YoY
100.0%
128.4%
Net Profit YoY
2.0%
63.8%
EPS (diluted)
$-0.04
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCH
PRCH
TARS
TARS
Q1 26
$121.1M
Q4 25
$112.3M
$151.7M
Q3 25
$115.1M
$118.7M
Q2 25
$107.0M
$102.7M
Q1 25
$84.5M
$78.3M
Q4 24
$75.3M
$66.4M
Q3 24
$77.7M
$48.1M
Q2 24
$75.9M
$40.8M
Net Profit
PRCH
PRCH
TARS
TARS
Q1 26
$-4.7M
Q4 25
$-3.5M
$-8.4M
Q3 25
$-10.9M
$-12.6M
Q2 25
$2.6M
$-20.3M
Q1 25
$8.4M
$-25.1M
Q4 24
$30.5M
$-23.1M
Q3 24
$14.4M
$-23.4M
Q2 24
$-64.3M
$-33.3M
Gross Margin
PRCH
PRCH
TARS
TARS
Q1 26
52.7%
Q4 25
99.5%
Q3 25
75.6%
Q2 25
70.9%
Q1 25
77.4%
Q4 24
Q3 24
79.4%
Q2 24
22.1%
Operating Margin
PRCH
PRCH
TARS
TARS
Q1 26
34.7%
Q4 25
14.7%
-5.3%
Q3 25
14.2%
-12.2%
Q2 25
4.7%
-21.6%
Q1 25
-1.5%
-33.5%
Q4 24
33.3%
-36.8%
Q3 24
-3.2%
-52.3%
Q2 24
-69.2%
-81.6%
Net Margin
PRCH
PRCH
TARS
TARS
Q1 26
-3.9%
Q4 25
-3.1%
-5.5%
Q3 25
-9.4%
-10.6%
Q2 25
2.4%
-19.8%
Q1 25
9.9%
-32.1%
Q4 24
40.5%
-34.8%
Q3 24
18.5%
-48.7%
Q2 24
-84.8%
-81.6%
EPS (diluted)
PRCH
PRCH
TARS
TARS
Q1 26
$-0.04
Q4 25
$0.00
$-0.17
Q3 25
$-0.10
$-0.30
Q2 25
$0.00
$-0.48
Q1 25
$0.07
$-0.64
Q4 24
$0.34
$-0.57
Q3 24
$0.12
$-0.61
Q2 24
$-0.65
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCH
PRCH
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$68.4M
$417.3M
Total DebtLower is stronger
$391.3M
$72.4M
Stockholders' EquityBook value
$26.3M
$343.4M
Total Assets
$806.6M
$562.2M
Debt / EquityLower = less leverage
14.87×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCH
PRCH
TARS
TARS
Q1 26
$68.4M
Q4 25
$57.3M
$417.3M
Q3 25
$85.0M
$401.8M
Q2 25
$79.8M
$381.1M
Q1 25
$70.4M
$407.9M
Q4 24
$191.7M
$291.4M
Q3 24
$238.6M
$317.0M
Q2 24
$308.4M
$323.6M
Total Debt
PRCH
PRCH
TARS
TARS
Q1 26
$391.3M
Q4 25
$392.8M
$72.4M
Q3 25
$387.1M
$72.3M
Q2 25
$394.1M
$72.1M
Q1 25
$409.2M
$72.0M
Q4 24
$403.9M
$71.8M
Q3 24
$399.0M
$71.7M
Q2 24
$436.8M
$71.6M
Stockholders' Equity
PRCH
PRCH
TARS
TARS
Q1 26
$26.3M
Q4 25
$-24.6M
$343.4M
Q3 25
$-27.9M
$335.1M
Q2 25
$-29.3M
$332.6M
Q1 25
$-52.4M
$342.5M
Q4 24
$-43.2M
$224.5M
Q3 24
$-77.0M
$237.5M
Q2 24
$-101.9M
$252.2M
Total Assets
PRCH
PRCH
TARS
TARS
Q1 26
$806.6M
Q4 25
$797.4M
$562.2M
Q3 25
$787.7M
$534.6M
Q2 25
$770.7M
$495.0M
Q1 25
$802.3M
$500.8M
Q4 24
$814.0M
$377.0M
Q3 24
$867.3M
$376.3M
Q2 24
$876.1M
$376.8M
Debt / Equity
PRCH
PRCH
TARS
TARS
Q1 26
14.87×
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCH
PRCH
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCH
PRCH
TARS
TARS
Q1 26
Q4 25
$1.2M
$19.3M
Q3 25
$40.8M
$18.3M
Q2 25
$35.6M
$-29.4M
Q1 25
$-11.2M
$-20.7M
Q4 24
$-26.6M
$-22.2M
Q3 24
$12.4M
$-8.7M
Q2 24
$-26.0M
$-14.4M
Free Cash Flow
PRCH
PRCH
TARS
TARS
Q1 26
Q4 25
$1.1M
$13.0M
Q3 25
$40.7M
$16.3M
Q2 25
$35.4M
$-30.4M
Q1 25
$-11.2M
$-21.2M
Q4 24
$-26.8M
$-22.3M
Q3 24
$12.2M
$-8.9M
Q2 24
$-26.0M
$-15.4M
FCF Margin
PRCH
PRCH
TARS
TARS
Q1 26
Q4 25
1.0%
8.6%
Q3 25
35.4%
13.8%
Q2 25
33.0%
-29.6%
Q1 25
-13.3%
-27.1%
Q4 24
-35.6%
-33.5%
Q3 24
15.7%
-18.6%
Q2 24
-34.3%
-37.8%
Capex Intensity
PRCH
PRCH
TARS
TARS
Q1 26
Q4 25
0.1%
4.2%
Q3 25
0.1%
1.6%
Q2 25
0.2%
1.0%
Q1 25
0.1%
0.8%
Q4 24
0.3%
0.1%
Q3 24
0.3%
0.6%
Q2 24
0.1%
2.5%
Cash Conversion
PRCH
PRCH
TARS
TARS
Q1 26
Q4 25
Q3 25
Q2 25
13.79×
Q1 25
-1.33×
Q4 24
-0.87×
Q3 24
0.86×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons